Literature DB >> 7900706

Prolonged disease-free survival following surgical debulking and high-dose cisplatin/doxorubicin in a patient with bulky metastases from giant cell tumor of bone refractory to "standard" chemotherapy.

D J Stewart1, R Belanger, R S Benjamin.   

Abstract

A 32-year-old man developed multiple pulmonary metastases from a giant cell tumor of bone. His metastases failed to respond to several chemotherapy regimens (high-dose methotrexate with folinic acid plus doxorubicin 90 mg/m2; cyclophosphamide + bleomycin + actinomycin D; mitoxantrone + dacarbazine; and cisplatin 110 mg/m2). He underwent surgical resection (incomplete) of > 1 kg of tumor from his right lung in March 1985, followed by chemotherapy with menogaril (to which he did not respond). In August 1985, he underwent surgical resection (again, incomplete) of > 1 kg of tumor from his left lung. At the time of surgery, the left and right lung tumors differed histopathologically, with giant cell tumor present in the right lung and sarcoma in his left lung. He received carmustine in October 1985 and mitomycin C in December 1985 without response. His multiple bilateral lung metastases had again become quite large by September 1986. At that time, he received doxorubicin 90 mg/m2 plus cisplatin 120 mg/m2, and for the first time experienced tumor reduction (minor response). He underwent a subtotal resection of right lung and chest wall metastases in December 1986, and underwent subtotal resection of left lung metastases in January 1987. Grossly visible residual tumor was left behind on both sides at the time of surgery, although none was apparent on chest radiograph. He received a final chemotherapy treatment with doxorubicin 90 mg/m2 plus cisplatin 120 mg/m2 on February 2, 1987. He remained free of evidence of residual or recurrent tumor at the time of last followup in February, 1994.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7900706     DOI: 10.1097/00000421-199504000-00010

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  9 in total

Review 1.  Giant cell tumor of bone: current treatment options.

Authors:  Keith M Skubitz
Journal:  Curr Treat Options Oncol       Date:  2014-09

Review 2.  Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.

Authors:  Vittoria Colia; Salvatore Provenzano; Nadia Hindi; Paolo G Casali; Silvia Stacchiotti
Journal:  Rep Pract Oncol Radiother       Date:  2016-01-13

3.  Giant cell tumor of bone: treatment and outcome of 214 cases.

Authors:  Maurice Balke; Laura Schremper; Carsten Gebert; Helmut Ahrens; Arne Streitbuerger; Gabriele Koehler; Jendrik Hardes; Georg Gosheger
Journal:  J Cancer Res Clin Oncol       Date:  2008-03-06       Impact factor: 4.553

4.  Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas.

Authors:  D J Stewart; S Dahrouge; M Wee; S Aitken; H Hugenholtz
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 5.  Giant cell tumor of the uterus: case report and response to chemotherapy.

Authors:  Keith M Skubitz; J Carlos Manivel
Journal:  BMC Cancer       Date:  2007-03-14       Impact factor: 4.430

6.  Histological Regression of Giant Cell Tumor of Bone Following RANK Ligand Inhibition.

Authors:  Martin F Dietrich; Dominick Cavuoti; Michael Landay; Yull E Arriaga
Journal:  J Investig Med High Impact Case Rep       Date:  2014-11-23

7.  Outcome of lung metastases due to bone giant cell tumor initially managed with observation.

Authors:  Shinji Tsukamoto; Giovanni Ciani; Andreas F Mavrogenis; Cristina Ferrari; Manabu Akahane; Yasuhito Tanaka; Michele Rocca; Alessandra Longhi; Costantino Errani
Journal:  J Orthop Surg Res       Date:  2020-11-07       Impact factor: 2.359

Review 8.  Metastatic giant cell tumour of bone: a narrative review of management options and approaches.

Authors:  Ruiwen Xu; Peter F M Choong
Journal:  ANZ J Surg       Date:  2022-02-10       Impact factor: 2.025

Review 9.  Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.

Authors:  Czar Louie Gaston; Robert J Grimer; Michael Parry; Silvia Stacchiotti; Angelo Paolo Dei Tos; Hans Gelderblom; Stefano Ferrari; Giacomo G Baldi; Robin L Jones; Sant Chawla; Paolo Casali; Axel LeCesne; Jean-Yves Blay; Sander P D Dijkstra; David M Thomas; Piotr Rutkowski
Journal:  Clin Sarcoma Res       Date:  2016-09-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.